[35] Pischon T, Boeing H, Hoffmann K, et
al. General and abdominal adiposity and risk of death in Europe[J]. N Engl J
Med, 2008 359(20):2105-2120.DOI:10. 1056/NEJMoa0801891. [36] Organization W H Waist circumference
and waist-hip ratio : report of a WHO expert consultation[C]. Geneva, 8-11
December 2008,. 2011. [37] Stevens J, Katz E G, Huxley R R Associations
between gender, age and waist circumference[J]. Eur J Clin Nutr,
2010,64(1):6-15.DOI:10. 1038/ejcn 2009.101. [38] Brunani A, Pema S, Soranna D, et al.
Body composition assessment using bioelectrical impedance analysis (BIA) in a
wide cohort of patients affected with mild to severe obesity[J].Clin Nutr, 2021
,40(6):3973-3981 .DOI:10.1016/j clnu.2021.04.033. [39] Palmas F, Cindin A. Guerra R, et al. Comparison
of computed tomography and dual-energy X ray absorptiometry in the evaluation
of body composition in patients with obesity[J]. Front Endocrinol (I ausanne),
2023,14:1161116.DOI:10.3389/fendo 2023. 1161116. [40] Lv H, Li M, Wang Z, et al Clinical practice
guideline for body composition assessment based on upper abdominal magnetic
resonance images annotated using artificial intelligence[J].Chin Med J (Engl),
2022,135(6):631-633 DOI:101097/CM900000000002002. [41] 陈家伦. 临床内分泌学[M].上海:上海科学技术出版社, 2011. [42] WS/T 423-2022, 7岁以下儿童生长标准[S].2022. [43] WS/T 586-2018,学龄儿童青少年超重与肥胖筛查[S] 2018. [44] Kalinderi K, Goula V, Sapountzi E, et al.
Syndromic and monogenic obesity: new opportunities due to genetic-based
pharmacological treatment[] Children (Basel),2024,11(2):153.DOI:10.
3390/children1 1020153. [45] 中华医学会内分泌学分会，中华中医药学会糖尿病分会，中国医师协会外科医师分会肥胖和糖尿病外科医师委员会，等.基于临床的肥胖症多学科诊疗共识(2021年版)[J].中华消化外科杂志, 2021,20(11):16 [46] Fahed G, Aoun L, Bou Z M, et al. Metabolic
Syndrome: Updates on Pathophysiology and Management in 2021[J]. Int J Mol Sci,
2022,23(2)-786.DOI:10.3390/jms23020786. [47] Preda A, Carbone F, Tirandi A, et al. Obesity
phenotypes and cardiovascular risk: from pathophysiology to clinical management[J].Rev
Endocr Metab Disord,2023, 24(5):901-919.DOI:10. 1007/s11154-023-09813-5. [48] Acosta A, Camilleri M, Abu D B, et al. Selection
of antiobesity medications based on phenotypes enhances weight loss. a
pragmatic trial in an obesity clinic[J] Obesity (Silver Spring), 2021
,29(4):662-671.DOI:10.1002/oby.23120. [49] Hurtado A M, Acosta A. Precision medicine and
obesity[J]. Gastroenterol Clin North Am,2021,50(1):127-139.DOI:10.1016/j.gtc
2020.10.005. [50] Sacoto D, Hurtado M D, Acosta A. Precision
medicine and obesity[J]. Handb Exp harmacol, 2022,274:467-485.DOI:10.1007/164_ _2021_
566. [51] Sharma A M, Kushner R F. A proposed clinical
staging systerm for obesity[J]. Int J Obes (Lond), 2009,33(3):289-295.DOI:10. 1038/jo 2009.2. [52] Guo F, Moellering D R Garvey W T. The progression
of cardiometabolic disease: validation of a new cardiometabolic disease staging system
applicable to obesity[J]. Obesity (Silver Spring), 2014.221):110-118.DOI:10.
1002/oby 20585. [53] Li Y, Teng D, Shi X, et al. Prevalence of
diabetes recorded in mainland China using 2018 diagnostic criteria from the
American Diabetes Association: national cross sectional study[J].BMJ,
2020,369:m997.DOI:10.1 136/bmj :m997. [54] Kivimaki M, Kuosma E, Ferrie J E, et al.
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled
analysis of individual-level data for 120 813 adults from 16 cohort studies from
the USA and Europe[J]. Lancet Public Health,201 ,2(6):e277-e285.DOI:10.1016/S2468-2667(17)30074-9. [55] Ndumele C
E, NeelandIJ, Tuttle K R, et al. A synopsis of the evidence for the science and
clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a
scientific statement from the American Heart Association[J].Circulation,2023,148(20):1636-1664.DOI:10.1161/I000000000001186. [56] 张弘玮，狄建忠,于泳浩等.胃旁路术对糖尿病肾病蛋白尿影响的随访研究[J].外科理论与实践, 2015,20(5):399 402. [57] Schauer P R, Bhatt D L, KirwanJ P, et
al. Bariatric surgery versus intensive medical therapy diabetes 5-year outcomes[J].N
Engl Med,201 7,376(7):641-651.DOI:10.1056/NEJMoa1600869. [58] 邹大进，张征，纪立农、缓解2型糖尿病中国专家共识[J]、中国糖尿病杂志,2021,29(9):641- -652.DO:10.3969/
issn.1006-6187.2021.09 .001. [59] Mingrone G, Panunzi S, De Gaetano A,
et al. Metabolic surgery versus conventional medical therapy in patients with
type 2 diabetes: 10-year follow-up of an open-label, single-centre,randomized controlled
trial[J].Lancet,202 1,397(10271):293-304.DOI:10. 1016/S0140-6736(20)32649-0. [60] Lean M E, Leslie W S, Barnes A C, et
al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial
(DiRECT) of continued support for weight loss maintenance in the UK:an extension
study[J].Lancet Diabetes Endocrinol,2024,12(4):233-
246.DOI:10.1016/S2213-8587(23)00385-6. [61] Zhu J, Zhang Y, Wu Y, et al. Obesity
and Dyslipidemia in Chinese Adults: A Cross-Sectional Study in Shanghai,
China[J]. Nutrients, 2022,14(11)-:2321 .DOI:10 3390/nu14112321. [62] 李梦伊,刘雁军,王桂琦，等.大中华减重与代谢手术数据库2023年度报告[]. 中国实用外科杂志，2024,44(05):552-563 DOI:10.19538/j .cjps
issn1005-2208 2024.05.15. [63] Nussbaumerova B, Rosolova H Obesity
and Dysipidemia[J]. Curr Atheroscler Rep,2023,25(12):947-
955.DOI:10.1007/s11883-023-01167-2. [64] 中华医学会心血管病学分 会高血压学组.肥胖相关性高血压管理的中国专家共识[J].中华心血管病杂志, 2016.44(3):212-219 [65] Hall M E, CohenJ B, ArdJ D, et al
Weight-Loss Strategies for Prevention and Treatment of Hypertension: A
Scientific Statement From the American Heart Association[]. Hypertension,2021,78(5):e38-e50.DOI:10.1161/HYP000000000000202. [66] Kennedy C, Hayes P, Salama S, et al.
The effect of semaglutide on blood pressure in patients without diabetes: a
systematic review and meta -analysis[J]. J Clin Med,2023,123):772 .DOI:10
3390/jcm12030772. [67] Lingvay I Mosenzon O, Brown K, et al
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights
from SURPASS clinical program[J]. Cardiovasc Diabetol, 2023,22(1):66
.DOI:10.1186/s1 2933-023-01797-5. [68] Schaffiner F, Thaler H. Nonalcoholic
fatty liver disease[J]. Prog Liver Dis, 1986,8:283-298 [69] Chalasani N, Younossi Z, Lavine J E,
et al. The diagnosis and management of nonalcoholic fatty liver disease:
Practice guidance from the American Association for the Study of Liver Diseases[J]
Hepatology, 2018,67(1):328-357.DOI:10.1002/hep.29367. [70] Diehl A M, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis[J] N Engl J Med, 2017,377(21):2063- 2072.DOI:10.1056NEJMra1503519. .............. 注：其它参考文献略。《肥胖症诊疗指南（2024年版）》Word版由中医启疾光网编辑整理。《肥胖症诊疗指南（2024年版）》pbf版下载地址：http://www.nhc.gov.cn/yzygj/s7659/202410/ae3948b3fc9444feb2ecd26fb2daa111.shtml |
